86-22-6 (溴苯那敏,Brompheniramine)

CAS号:
86-22-6
中文名称:
溴苯那敏
英文名称:
Brompheniramine
分子式:
C16H19BrN2
分子量:
319.239463090897
简介:
Brompheniramine ((±)-Brompheniramine) 是一种有效的口服有效的烷基胺类抗组胺药。Brompheniramine 是一种选择性组胺 H1 受体 (histamine H1 receptor) 拮抗剂,Kd 为 6.06 nM。Brompheniramine 可阻断 hERG 通道 (hERG channels)、钙离子通道 (calcium channels) 和钠离子通道 (sodium channels),IC50 分别为 0.90 μM、16.12 μM 和 21.26 μM。Brompheniramine 具有抗胆碱能、抗抑郁以及麻醉作用,可用于过敏性鼻炎和缓解疼痛的研究。

溴苯那敏(86-22-6)名称与标识符

名称

中文别名:
溴苯那敏;3-(4-溴苯基)-N,N-二甲基-3-吡啶-2-基-1-丙胺;
英文别名:
Brompheniramine;3-(4-Bromophenyl)-N,N-dimethyl-3-pyridin-2-yl-propan-1-amine;Lodrane;CS-0013144;LS-130308;AB00053703_20;UNII-H57G17P2FN;EINECS 201-657-8;Q2606497;BSPBio_002641;KBio3_001861;C06857;C16H19BrN2;Prestwick3_000475;brompheniramin-;NCGC00015146-21;BRD-A68723818-050-05-1;[3-(4-Bromo-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine;2-[p-Bromo-.alpha.-[2-(dimethylamino)ethyl]benzyl]pyridine;BROMPHENIRAMINE [WHO-DD];SDCCGSBI-0050189.P004;NCGC00015146-07;AC-15955;BROMPHENIRAMINE [INN];gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine;Brompheniramine [INN:BAN];Dexbrompheniramine Brompheniramine;Dimetane (Salt/Mix);NCGC00015146-17;Brompheniraminum [INN-Latin];Prestwick2_000475;(6R,7R)-7-Amino-8-oxo-3-(1-propenyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid;3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine;(?)-Brompheniramine;bromphen;BROMPHENIRAMINE [MI];Dexbrompheniramine maleate salt;Brompheniramine (INN);NCGC00015146-05;KBio2_007298;Pyridine, 2-(p-bromo-alpha-(2-(dimethylamino)ethyl)benzyl)-;Spectrum5_001537;KBio2_004730;BROMPHENIRAMINE [VANDF];HY-B0480A;AB00053703_19;Parabromdylamine;D08VXO;CCG-204296;LS-177900;CHEMBL811;CS-O-06170;NCGC00015146-08;2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine;Spectrum_001682;AKOS005711313;SBI-0050189.P003;(+/-)-Brompheniramine;Bromphen; Brompheniramine; Parabromdylamine; Parabromodylamine;(+)-Brompheniramine; (+)-Parabromdylamine; (S)-Brompheniramine;Ilvin;AB00053703;[3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine;GTPL7133;Spectrum2_001610;KBio2_002162;NCGC00089782-02;Spectrum3_000981;3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridyl)propan-1-amine;SpecPlus_000750;Oprea1_690847;H57G17P2FN;FT-0603299;BROMPHENIRAMINE [HSDB];BSPBio_000610;86-22-6;Drauxin (Salt/Mix);CHEBI:3183;para-Bromdylamine;HSDB 3017;SPBio_002549;2-Pyridinepropanamine, .gamma.-(4-bromophenyl)-N,N-dimethyl-;Brotane;PDSP2_000145;Allent (Salt/Mix);L001031;STL058559;SCHEMBL4814;Antihistamine compound;Bromopheniramine;Brompheniramine Maleate (1:1);Prestwick0_000475;Pyridine, 2-[p-bromo-.alpha.-[2-(dimethylamino)ethyl]benzyl]-;[3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine;BPBio1_000672;C16-H19-Br-N2;KBioGR_001554;D07543;Parabromodylamine;1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane;Lopac0_000201;DTXSID5022691;Prestwick1_000475;ZDIGNSYAACHWNL-UHFFFAOYSA-N;Brotane (TN);3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine;Brompheniraminum;DB00835;p-Bromdylamine;156428-33-0;PDSP1_000146;BRD-A68723818-050-18-4;Spectrum4_001107;()-Brompheniramine;Bromphen; Brompheniramine; Parabromdylamine; Parabromodylamine;DivK1c_006846;KBio1_001790;2-[p-bromo-alpha-(2-dimethylaminoethyl)benzyl]pyridine;3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine;2-Pyridinepropanamine, gamma-(4-bromophenyl)-N,N-dimethyl-;SPBio_001619;EN300-18563906;KBioSS_002162;BDBM50017666;3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine;HMS3604F03;NCGC00015146-04;FT-0772799;LS-187224;Pyridine, 2-[p-bromo-α-[2-(dimethylamino)ethyl]benzyl]- (6CI, 7CI, 8CI);γ-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine (ACI);(±)-Brompheniramine;2-[p-Bromo-α-(2-dimethylaminoethyl)benzyl]pyridine;MeSH ID: D001977;Brompheniramine Free Base;G90918;Dimetapp Allergy;DB-056920;BRD-A68723818-050-31-7;Dimetane;Bromfeniramina [INN-Spanish];Bromfenex;Dimetane-ten;NS00007169;SBI-0050189.0002;Bromfeniramina;Bromfed;BRD-A68723818-050-32-5;

标识符

InChIKey:
ZDIGNSYAACHWNL-UHFFFAOYSA-N
Inchi:
1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
SMILES:
BrC1C=CC(C(CCN(C)C)C2C=CC=CN=2)=CC=1

溴苯那敏(86-22-6)物化性质

实验特性

  • LogP : log Kow = 4.06 (est)
  • 折射率 : 1.5770 (estimate)
  • 沸点 : bp0.5 147-152°
  • 熔点 : 25°C
  • 密度 : 1.3740 (rough estimate)

计算特性

  • 精确分子量 : 318.07316g/mol
  • 氢键供体数量 : 0
  • 氢键受体数量 : 2
  • 可旋转化学键数量 : 5
  • 同位素质量 : 318.07316g/mol
  • 重原子数量 : 19
  • 复杂度 : 249
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 1
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 无
  • 互变异构体数量 : 2
  • 表面电荷 : 0
  • 拓扑分子极性表面积 : 16.1Ų

溴苯那敏(86-22-6)国际标准相关数据

EINECS:
201-657-8

溴苯那敏(86-22-6)合成路线

合成路线:1 步
反应条件:
参考文献:
Photoinduced Three-Component Carboarylation of Unactivated Alkenes with Protic C(sp3)-H Feedstocks
Hong, Yang; et al, Organic Letters, 2022, 24(41), 7677-7684
合成路线:1 步
反应条件:
参考文献:
New Synthetic Route to Pheniramines via Hydroformylation of Functionalyzed Olefins
Botteghi, Carlo; et al, Journal of Organic Chemistry, 1994, 59(23), 7125-7
合成路线:1 步
反应条件:
参考文献:
New Synthetic Route to Pheniramines via Hydroformylation of Functionalyzed Olefins
Botteghi, Carlo; et al, Journal of Organic Chemistry, 1994, 59(23), 7125-7
合成路线:2 步
反应条件:
参考文献:
New Synthetic Route to Pheniramines via Hydroformylation of Functionalyzed Olefins
Botteghi, Carlo; et al, Journal of Organic Chemistry, 1994, 59(23), 7125-7
合成路线:2 步
反应条件:
参考文献:
Photoinduced Three-Component Carboarylation of Unactivated Alkenes with Protic C(sp3)-H Feedstocks
Hong, Yang; et al, Organic Letters, 2022, 24(41), 7677-7684
合成路线:3 步
反应条件:
参考文献:
Photoinduced Three-Component Carboarylation of Unactivated Alkenes with Protic C(sp3)-H Feedstocks
Hong, Yang; et al, Organic Letters, 2022, 24(41), 7677-7684
合成路线:3 步
反应条件:
参考文献:
New Synthetic Route to Pheniramines via Hydroformylation of Functionalyzed Olefins
Botteghi, Carlo; et al, Journal of Organic Chemistry, 1994, 59(23), 7125-7